We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Early Pregnancy Glycemic Testing Enhances Gestational Diabetes Prediction: Insights from the GO MOMs Study

MedXY Editorial Team•Oct 3, 2026•Diabetes & Endocrinology
continuous glucose monitoringEarly Pregnancy ScreeningGestational diabetes mellituslarge-for-gestational-ageOral Glucose Tolerance Test

Highlight

  • Early pregnancy (10-14 weeks) oral glucose tolerance test (OGTT) and continuous glucose monitoring (CGM) data improve prediction of gestational diabetes mellitus (GDM) beyond clinical factors alone.
  • Adding OGTT to clinical risk factors increased the positive predictive value for GDM from 12.2% to 26.5% while maintaining a high negative predictive value (≥96%).
  • Neither early pregnancy OGTT nor CGM added predictive value for large-for-gestational-age (LGA) birth weights over clinical factors.
  • These findings support potential benefits of early glycemic assessment to identify women at risk for GDM and guide earlier interventions.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutic Glucura Combined with CGM Shows Superior 6-Month OutcomesA randomized trial demonstrates that adding the digital therapeutic glucura to intermittent CGM and standard care significantly improves HbA1c, weight loss, and mental health in non-insulin-treated type 2 diabetes patients over six months.Oct 5, 2026Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutics Combined with CGM Show Superior OutcomesA 6-month RCT in non-insulin-treated type 2 diabetes demonstrates that combining the digital therapeutic glucura with CGM significantly improves HbA1c, weight, and patient well-being beyond CGM and standard care alone.Oct 3, 2026Worsening Time in Range as a Predictor of Microvascular Complications in Type 1 Diabetes: Insights from a 5-Year Real-World StudyA 5-year real-world cohort study reveals that declines in CGM-derived time in range correlate with increased microvascular complications in type 1 diabetes, offering prognostic value beyond HbA1c.Sep 27, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Longitudinal Glycemic Trajectories in Adults with Type 1 Diabetes: Insights from a Three-Year Multicenter CGM Study
This study investigates three-year continuous glucose monitoring trajectories across clinical subgroups of adults with type 1 diabetes to identify factors influencing glycemic control and variability, highlighting the need for individualize
Sep 21, 2026
Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort StudyThis study reveals that polyendocrine metabolic ovarian syndrome (PMOS) during pregnancy increases risks of early gestational diabetes and adverse neonatal outcomes, underscoring the need for timely identification and management to improveSep 21, 2026
Continuous Glucose Monitoring Using the FreeStyle Libre Pro iQ in Presymptomatic Type 1 Diabetes: Advancements in Early Detection and Risk StratificationThis review examines the role of FreeStyle Libre Pro iQ CGM in differentiating presymptomatic stages of type 1 diabetes and predicting progression to clinical disease, comparing its performance with Dexcom G6 and discussing implications forSep 12, 2026